Patisiran uses siRNA to inhibit abnormal transthyretin (TTR) production, caused by a mutation in the TTR gene, to treat the resulting disease hereditary transthyretin-mediated amyloidosis (hATTR). Here, TTR is linked to familial amyloid neuropathy.